Background: β-Lactam resistance genotype trends in clinical isolates of Haemophilus influenzae and their correlation with the clinical background were analyzed. Methods: Five hundred and ten respiratory isolates of H. influenzae collected during the period 2002–2009 were classified by PCR into gBLNAS (genotype for β-lactamase-negative ampicillin-susceptible), gBLNAR (genotype for β-lactamase-negative ampicillin-resistant) and 3 other genotypes. The associations with host clinical data and antimicrobial susceptibility were analyzed in all 144 isolates between 2008 and 2009. Results: The 8-year trend analysis detected an increase in gBLNAR with a decrease in gBLNAS. The probability of being a causative pathogen did not differ between genotypes. Host clinical characteristics such as age and gender did not differ with gBLNAR or gBLNAS, but the underlying respiratory diseases did differ. gBLNAR was found at the highest rate in 83% of isolates from patients with nontuberculous mycobacteriosis. In contrast, gBLNAR accounted for as little as 33% of isolates from chronic obstructive pulmonary disease. Conclusions: There were no differences in the pathogenicity of gBLNAR and gBLNAS. The underlying respiratory diseases may be related to the resistance genotype.

Keywords:
Haemophilus influenzae, β-Lactam resistance, Respiratory tract infection
1.
Bhusal Y, Mihu CN, Tarrand JJ, Rolston KV: Incidence of fluoroquinolone-resistant and extended-spectrum β-lactamase-producing Escherichia coli at a Comprehensive Cancer Center in the United States. Chemotherapy 2011;57:335–338.
2.
Mohammadtaheri Z, Pourpaki M, Mohammadi F, Namdar R, Masjedi MR: Surveillance of antimicrobial susceptibility among bacterial isolates from intensive care unit patients of a tertiary-care university hospital in Iran: 2006–2009. Chemotherapy 2010;56:478–484.
3.
Kofterids DP, Notas G, Maraki S, Anastasopoulos T, Papazoglou G, Zisiou AT, Mantadakis E, Samonis G: Antimicrobial susceptibilities of 930 Haemophilus influenzae clinical strains isolated from the island of Crete, Greece. Chemotherapy 2008;54:492–498.
4.
Ubukata K, Shibasaki Y, Yamamoto K, Chiba N, Hasegawa K, Takeuchi Y, Sunakawa K, Inoue M, Konno M: Association of amino acid substitutions in penicillin-binding protein 3 with β-lactam resistance in β-lactamase-negative ampicillin-resistant Haemophilusinfluenzae. Antimicrob Agents Chemother 2001;45:1693–1699.
5.
Ubukata K: Problems associated with high prevalence of multidrug-resistant bacteria in patients with community-acquired infections. J Infect Chemother 2003;9:285–291.
6.
Kishii K, Chiba N, Morozumi M, Hamano-Hasegawa-K, Kurokawa I, Masaki J, Ubukata K: Diverse mutations in the ftsI gene in ampicillin-resistant Haemophilus influenzae isolates from pediatric patients with acute otitis media. J Infect Chemother 2010;16:87–93.
7.
Hotomi M, Fujihara K, Billal D, Suzuki K, Nishimura T, Baba S, Yamanaka N: Genetic characteristics and clonal dissemination of β-lactamase-negative ampicillin-resistant Haemophilusinfluenzae strains isolated from the upper respiratory tract of patients in Japan. Antimicrob Agents Chemother 2007;51:3969–3976.
8.
Skaare D, Allum AG, Anthonisen IL, Jenkins A, Lia A, Strand L, Tveten Y, Kristiansen BE: Mutant ftsI genes in the emergence of penicillin-binding protein-mediated β-lactam resistance in Haemophilus influenzae in Norway. Clin Mirobiol Infect 2010;16:1117–1124.
9.
Yoshizumi S, Takahashi Y, Watanabe Y, Okezaki E, Ishii Y, Tateda K: In vitro antibacterial activities of new fluoroquinolones against clinical isolates of Haemophilus influenzae with ciprofloxacin-resistance-associated alterations in GyrA and ParC. Chemotherapy 2004;50:265–275.
10.
Clinical and Laboratory Standard Institute: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, M7-A7. Approved standard, ed 7. Wayne, Clinical and Laboratory Standards Institute, 2006.
11.
Kubota T, Higa F, Kusano N, Nakasone I, Haranage S, Tateyama M, Yamane N, Fujita J: Genetic analyses of beta-lactamase negative ampicillin-resistant strains of Haemophilus influenzae isolated in Okinawa, Japan. Jpn J Infect 2006;59:36–41.
12.
Sevillano D, Giménez MJ, Cercenado E, Cafini F, Gené A, Alou L, Marco F, Martínez-Martínez L, Coronel P, Aguilar L: Genotypic versus phenotypic characterization, with respect to β-lactam susceptibility, of Haemophilus influenzae isolates exhibiting decreased susceptibility to beta-lactam resistance markers. Antimicrob Agents Chemother 2009;53:267–270.
13.
Barbosa AR, Giufrè M, Cerquetti M, Bajanca-Lavado MP: Polymorphism in ftsI gene and β-lactam susceptibility in Portuguese Haemophilus influenzae strains: clonal dissemination of β-lactamase-positive isolates with decreased susceptibility to amoxicillin/clavulanic acid. J Antimicrob Chemother 2011;66:788–796.
14.
Watanuki Y, Odagiri S, Takahashi H, Ogura T, Tomioka T: Pathogenesis of β-lactam-resistant Haemophilus influenzae isolated from sputum (in Japanese). Kansenshogaku Zasshi 2004;78:873–878.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.